| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Encompass Health Corporation Common Stock$111.06
+0.48 (+0.43%)
Market Cap
10.66 B
EPS
5.62
P/E Ratio
19.35 $
Value Trade
71.84 M
SEC Financials
Q1 2026Dilution Risk
Revenue
1.59 B
Operating CF
313.10 M
Total Assets
7.31 B
Total Liabilities
3.95 B
Equity
2.52 B
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
227.60 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 1, 2026
Overview
Volume
423.40 K
52 Week Range
92.77 - 127.99
% held by Insiders
1.22 %
% held by Institutions
99.53 %
Enterprise Value
14.07 B
Total Shares
99.24 M
Short %
3.17 %
Float Shares
98.15 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in EHC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
EHC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-EHC
Jul 23, 2026▲ +0.4%today
Encompass Health increases and declares dividend on common stock
Encompass Health Corp. announced a $0.02 increase in its quarterly dividend, raising it to $0.21 per share. The dividend is payable on October 15, 2026, to shareholders on record as of October 1, 2026. The company is recognized for its leadership in inpatient rehabilitation with a significant national footprint.
Read more →-EHC
Jul 9, 2026Encompass Health announces date of 2026 second quarter earnings call
Encompass Health Corp. has announced its second quarter earnings call for 2026, scheduled for August 6, 2026. The company will report its results after market close on August 5, 2026. Investors can access the call via phone or through a live webcast on the company's investor website.
Read more →-EHC
May 29, 2026Encompass Health to build 36-bed inpatient rehabilitation hospital in Bridgeport, West Virginia
Encompass Health Corp. plans to build a new 36-bed inpatient rehabilitation hospital in Bridgeport, West Virginia, relocating from its former 19-bed unit. The new facility will enhance access to rehabilitation services, featuring private rooms and advanced therapy equipment. The hospital aims to serve patients recovering from serious conditions, including strokes and orthopedic issues.
Read more →-EHC
May 14, 2026Encompass Health announces private offering of senior notes
Encompass Health Corp. has announced a private offering of $500 million in senior notes maturing in 2034. The proceeds will be used to redeem $400 million of existing senior notes due 2028 and repay $100 million of its revolving credit facility. The offering is targeted at qualified institutional buyers and is subject to market conditions.
Read more →-EHC
May 14, 2026Encompass Health issues notice for partial redemption of its 4.500% senior notes due 2028
Encompass Health Corp. announced the redemption of $400 million of its 4.500% senior notes due 2028, set for June 13, 2026. The company anticipates a $3.2 million loss on this early debt extinguishment. The total outstanding principal of these notes was $800 million as of May 14, 2026.
Read more →-EHC
May 14, 2026Encompass Health announces pricing of $500 million of senior notes due 2034 in a private offering
Encompass Health Corp. has announced the pricing of a private offering of $500 million in senior notes due 2034, with a 5.875% interest rate. The company plans to use the proceeds to redeem existing notes and repay part of its revolving credit facility. The offering is expected to close on May 29, 2026, pending customary conditions.
Read more →-EHC
May 14, 2026Polly Manuel 205-970-5912 Media encompasshealth.com Investor relations contact Mark Miller 205-970-5860 Mark.Miller encompasshealth.com Encompass Health announces pricing of $500 million of senior notes due
Encompass Health Corp. has announced the pricing of a private offering for $500 million of 5.875% senior notes due 2034. The notes will pay semiannual interest and are intended to close on May 29, 2026. The proceeds from the offering will be used to redeem existing senior notes due 2028, repay outstanding amounts under the company's revolving credit facility, and pay related fees. The offering is aimed at institutional buyers and will not be registered under the Securities Act, highlighting the tight regulatory framework surrounding such deals.
Read more →-EHC
May 11, 2026Encompass Health announces plans to build a 50-bed inpatient rehabilitation hospital in Post Falls, Idaho
Encompass Health Corp. plans to construct a 50-bed inpatient rehabilitation hospital in Post Falls, Idaho, aimed at serving patients recovering from serious illnesses and injuries. The facility will offer specialized therapies and advanced rehabilitation technology. Expected to open in 2028, it will expand the company's presence in Idaho, addressing the growing need for rehabilitation services in the region.
Read more →-EHC
May 7, 2026Encompass Health declares dividend on common stock
Encompass Health Corp. has announced a quarterly cash dividend of $0.19 per share, payable on July 15, 2026. This decision reflects the company's strong financial position and commitment to returning value to shareholders. Encompass Health is a prominent operator of inpatient rehabilitation hospitals across the U.S., recognized for its quality care and innovative treatments.
Read more →-EHC
Apr 23, 2026Encompass Health to participate in BofA Securities 2026 Health Care Conference
Encompass Health Corp. will participate in the BofA Securities 2026 Health Care Conference from May 12-14, 2026. CFO Doug Coltharp will engage in a fireside chat on May 12, 2026, which will be available via live webcast. The company is noted for its leadership in inpatient rehabilitation care across the U.S.
Read more →-EHC
Apr 22, 2026Encompass Health and Cookeville Regional Medical Center announce plans to build a 40-bed inpatient rehabilitation hospital in Cookeville, Tennessee
Encompass Health and Cookeville Regional Medical Center are collaborating to establish a 40-bed inpatient rehabilitation hospital in Cookeville, Tennessee. This facility aims to meet the increasing demand for rehabilitation services in the region, providing specialized care for patients recovering from various conditions. The hospital is expected to open in 2027, featuring private rooms and advanced therapy technologies.
Read more →-EHC
Sep 9, 2019Hillary Carnel | 205 970-5912 hillary.carnel@encompasshealth.com Investor Relations Contact: Crissy Carlisle | 205 970-5860 crissy.carlisle@encompasshealth.com Encompass Health prices offering of its 4.500
Hillary Carnel | 205 970-5912 hillary.carnel@encompasshealth.com Crissy Carlisle | 205 970-5860 crissy.carlisle@encompasshealth.com Health prices offering of its 4.500% senior notes due 2028 and its 4.750% senior notes due 2030 BIRMINGHAM, Ala., Sept. 9, 2019 Encompass Heal
Read more →-EHC
Apr 1, 2019Encompass Health Contacts: Media: Hillary Carnel, 205 970-5912 hillary.carnel@encompasshealth.com Investor Relations: Crissy Carlisle, 205 970-5860 crissy.carlisle@encompasshealth.com Encompass Health announces definitiv
Encompass Health Contacts: Media: Hillary Carnel, 205 970-5912 hillary.carnel@encompasshealth.com Investor Relations: Crissy Carlisle, 205 970-5860 crissy.carlisle@encompasshealth.com Encompass Health announces definitive agreement to acquire Birmingham based Alacare Home Health
Read more →-EHC
Mar 15, 2018Encompass Health Contacts: Media: Hillary Carnel, 205 767-9654, hillary.carnel@encompasshealth.com Investor Relations: Crissy Carlisle, 205 970-5860, crissy.carlisle@encompasshealth.com Encompass Health announces definit
Encompass Health Contacts: Media: Hillary Carnel, 205 767-9654, hillary.carnel@encompasshealth.com Investor Relations: Crissy Carlisle, 205 970-5860, crissy.carlisle@encompasshealth.com Encompass Health announces definitive agreement to acquire Camellia Healthcare Adds new geog
Read more →Competitive Position
How EHC ranks across every disease it competes inCompetitive Position is a premium feature
See how EHC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial